<DOC>
	<DOCNO>NCT01978184</DOCNO>
	<brief_summary>This randomized phase II trial examine ability hydroxychloroquine improve clinical activity pre-operative regimen gemcitabine nab-paclitaxel subject potentially resectable adenocarcinoma pancreas . Eligible subject receive 2 cycle gemcitabine nab-paclitaxel ( day 1 , 8 , 15 ) without hydrocychloroquine follow surgical resection . Primary endpoint histologic response grade Evans criterion . Secondary endpoint CA19-9 response PET response . Pre post treatment tissue biopsy obtain assess level autophagy tumor , liver peripheral blood .</brief_summary>
	<brief_title>Randomized Phase II Trial Pre-Operative Gemcitabine Nab Paclitacel With With Out Hydroxychloroquine</brief_title>
	<detailed_description />
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Hydroxychloroquine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<criteria>Subjects biopsyproven potentially resectable borderline adenocarcinoma pancreas determine National Comprehensive Cancer Network ( NCCN ) criterion Karnofsky performance status 70100 % No active second malignancy except basal cell carcinoma skin Patient adequate biological parameter demonstrate follow blood count screen Absolute neutrophil count ( ANC ) ≥1.5 × 109/L ; Platelet count ≥100,000/mm3 ( 100 × 109/L ) ; Hemoglobin ( Hgb ) ≥9 g/dL . Patient follow blood chemistry level Baseline aspartate aminotransferase ( AST ) ( SGOT ) , Alanine transaminase ( SGPT ) ≤2.5 × upper limit normal range ( ULN ) Total bilirubin ≤ULN Serum Creatinine ≤ 1.5mg/dl OR calculate creatinine clearance ≥ 50 patient creatinine great 1.5 Prothrombin time ( PT ) within normal limit ( WNL ) . If patient warfarin prophylactic clot presentation indwell catheter , Partial PT/PTT may +/ 15 % thromboplastin time ( PTT ) WNL . If patient warfarin prophylactic clot presentation indwell catheter , PT/PTT may +/ 15 % Age &gt; 18 year . Patient must able swallow enteral medication requirement feed tube . Patient 's must intractable nausea vomit prohibits patient oral medication Ability understand willingness sign write informed consent document . Subjects deem surgically unresectable subject unwilling undergo surgical resection . Subjects receive chemotherapy within 12 month prior randomization . Prior use radiotherapy investigational agent pancreatic cancer . Any evidence metastasis distant organ ( liver , lung , peritoneum ) . Symptomatic evidence gastric outlet obstruction Inability adhere study and/or followup procedure History allergic reaction hypersensitivity study drug ( hydroxychloroquine , gemcitabine , abraxane ) . Women childbearing potential men must agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) prior study entry duration study participation . All female childbearing potential must blood test urine study within two week prior randomization rule pregnancy . Patients porphyria ineligible . Patients psoriasis ineligible unless disease well control care specialist agree monitor patient exacerbation . Patients require use enzymeinducing antiepileptic medication include : phenytoin , carbamazepine , phenobarbital , primidone oxcarbazepine exclude . Patients previously document macular degeneration diabetic retinopathy exclude . Baseline electrocardiogram ( EKG ) correct QT interval ( QTc ) &gt; 470 msec ( include subject medication ) . Subjects ventricular pacemaker QT interval measurable eligible casebycase basis . Patient history interstitial lung disease , history slowly progressive dyspnea , sarcoidosis , silicosis , idiopathic pulmonary fibrosis pulmonary hypersensitivity pneumonitis Patient know active infection HIV , Hepatitis B Hepatitis C Patients require use warfarin therapeutic purpose .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Pancreatic Cancer , resectable adenocarcinoma pancreas</keyword>
</DOC>